News Headlines Article

Portola Pharmaceuticals starts Phase III test of emergency bleeding drug
San Francisco Business Times

Portola Pharmaceuticals Inc. started enrolling patients in a late-stage clinical trial of a treatment for major bleeding in patients taking common anticoagulants. The South San Francisco company (NASDAQ: PTLA) intends the drug — andexanet alfa — to counteract anticoagulant drugs that some patients take for short-term or chronic conditions. Those oral anticoagulants inhibit Factor Xa, which causes blood to clot, and though that’s quite helpful in people at risk of too much clotting like deep vein thrombosis or pulmonary embolism, the lack of clotting factor can be a terrible problem if the patients have severe bleeding or require emergency surgery.